Ian Rowe

@IanARowe

Associate Professor & Hepatologist at University of Leeds. Interested in outcomes in liver disease. President elect BASL. Views my own.

Leeds, England rowe-liver.com Joined November 2012

1.2K Following 2.3K Followers 2.2K Posts

Latest posts 5

Pinned post

Ian Rowe @IanARowe Jun 4, 2021

The placebo response in #NASH, simply explained

@AGA_CGH tinyurl.com/dkvfxhd4

1⃣ Sampling variability explains the majority of the placebo response

2⃣Fibrosis progression in trials slower than in observational studies

3⃣Is liver biopsy a reliable endpoint? #LiverTwitter

Ian Rowe @IanARowe Dec 20, 2025

Conference abstracts serve a purpose for students and trainees

There is the experience of doing the work

It gives people a chance to be part of the community, to meet experts and future collaborators and colleagues

@basl_events the poster round is the BEST part of the meeting

Elliot Tapper @ebtapper Dec 20, 2025

In defense of conference abstracts

I went to @DDWMeeting in 2009 as a medical student. I worked HARD to produce an abstract. I learned a TON. I was in AWE of all the talks from people whose papers I read. An EXPERT came by my poster and destroyed it. I will NEVER forget

1/
View quoted post on X

Ian Rowe @IanARowe Nov 27, 2025

Great fun think about this for @JHepatology

Need to think about whole patient benefit of treatment for individuals with #MASLD and other metabolic multi morbidity

Many patients with MASLD will receive effective treatment before hepatology involvement

Ezequiel Mauro @ezemauro_ok Nov 27, 2025

Brilliant editorial by @IanARowe: A “typical" (T2DM, HTA, BMI 34, DLP) at-risk MASH patient faces ~12% 10yr CV risk but only 1-3% liver-event risk. This gap shows management should prioritise weight loss and metabolic control before liver-directed therapy.journal-of-hepatology.eu/article/S0168-…
View quoted post on X

Ian Rowe @IanARowe May 8, 2025

Privileged to be part of this wide-ranging discussion #EASLStudio at the #EASLCongress

We explored lots of the important issues around screening for liver disease and why it is critical that we build the evidence base to support it

Free to watch back, it's worth the time!

EASL Education Verified account @EASLedu May 8, 2025

Watch #EASLStudio to find out how are projects like @LIVERAiM are aiming to change the game when it comes to diagnosing #LiverDiseases early

📅Starting at 16:15 CEST
📍Onsite: Hepatology Arena
💻Online: : easl.eu/studio-at-easl…

@EASLnews @aelsharkawy75 @majathiele @IanARowe
@Yujun__Wong @apichatka @BavenoCoop

#EASLCongress
View quoted post on X

Ian Rowe @IanARowe May 7, 2025

Really looking forward to these conversations, lots of unresolved issues and questions to be answered

Come along and hear what we still need to understand

#EASLCongress

EASL Education Verified account @EASLedu May 7, 2025

Tune in to this episode of #EASLStudio as the faculty explores the pros and cons of early screening.

📅Thursday, 8 May at 16:15 CEST
📍Onsite: Hepatology Arena
💻Online: : easl.eu/studio-at-easl…

@EASLNews @aelsharkawy75 @majathiele @IanARowe @LiverAim @Yujun__Wong @apichatka @BavenoCoop

#LiverX #EASLCongress

View quoted post on X